Author Response: Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women

Objective:To prospectively examine the associations between long-term dietary flavonoids and subjective cognitive decline (SCD).Methods:We followed 49,493 women from the Nurses’ Health Study (NHS) (1984-2006) and 27,842 men from the Health Professionals Follow-up Study (HPFS) (1986-2002). Poisson regression was used to evaluate the associations between dietary flavonoids (flavonols, flavones, flavanones, flavan-3-ols, anthocyanins, polymeric flavonoids, and proanthocyanidins) and subsequent SCD. For the NHS, long-term average dietary intake was calculated from seven repeated food frequency questionnaires (SFFQs), and SCD was assessed in 2012 and 2014. For the HPFS, average dietary intake was calculated from five repeated SFFQs, and SCD assessed in 2008 and 2012.Results:Higher intake of total flavonoids was associated with lower odds of SCD after adjusting for age, total energy intake, major non-dietary factors, and specific dietary factors. Comparing the highest versus the lowest quintiles of total flavonoid intake, the pooled multivariable-adjusted odds ratios (ORs) (95% CIs) of 3-unit increments in SCD was 0.81 (0.76, 0.89). In the pooled results, the strongest associations were observed for flavones (OR=0.62 [0.57, 0.68]), flavanones (0.64 [0.58, 0.68)]), and anthocyanins (0.76 [0.72, 0.84]) (p trend <0.0001 for all groups). The dose-response curve was steepest for flavones, followed by anthocyanins. Many flavonoid-rich foods, such as strawberries, oranges, grapefruits, citrus juices, apples/pears, celery, peppers, and bananas, were significantly associated with lower odds of SCD.Conclusion:Our findings support a benefit of higher flavonoid intakes for maintaining cognitive function in US men and women.

Download Full-text

A Prospective Study of Dietary Flavonoid Intake and Risk of Glioma in US Men and Women

Current Developments in Nutrition ◽

10.1093/cdn/nzab036_005 ◽

2021 ◽

Vol 5 (Supplement_2) ◽

pp. 263-263

Author(s):

Alaina Bever ◽

Aedin Cassidy ◽

Eric Rimm ◽

Meir Stampfer ◽

David Cote

Keyword(s):

Total Flavonoid ◽

Health Study ◽

Men And Women ◽

Funding Sources ◽

Flavonoid Intake ◽

Glioma Risk ◽

Dietary Flavonoid ◽

Incident Cases

Abstract Objectives Flavonoids are a diverse group of plant constituents with demonstrated neuroprotective and anti-tumor effects. Flavonoid intake may decrease glioma risk, an association that has not yet been investigated in humans. The objective of this study was to evaluate the association between dietary flavonoid consumption and glioma risk in participants in the female Nurses’ Health Study (1984–2014, n = 81,688) and Nurses’ Health Study II (1991–2017, n = 95,228), and the male Health Professionals Follow-up Study (1986–2014, n = 49,884). Methods Exposure was average long-term (up to 30 years) and recent (up to 12 years) intake of total flavonoids and six flavonoid subclasses, derived from validated quadrennial food frequency questionnaires. The primary outcome was incident glioma, confirmed by medical record review. Results We documented 536 incident cases of glioma across 5,936,386 person-years of follow-up. Long-term total flavonoid, flavan-3-ol, and polymer intake was associated with decreased glioma risk in pooled analyses comparing highest to lowest quintile of consumption (total flavonoid hazard ratio (HR) = 0.79, 95% CI: 0.59–1.05, P-trend = 0.04; flavan-3-ol HR = 0.76, 95% CI: 0.57–1.01, P-trend = 0.04; polymer HR = 0.82, 95% CI: 0.61–1.09, P-trend = 0.05). Associations with recent intake were weaker and not statistically significant. There were no associations with other flavonoid subclasses. After additional adjustment for tea consumption, there was no significant association between flavan-3-ol or polymer consumption and glioma. Conclusions Increased dietary intake of flavan-3-ol and polymeric flavonoids, especially those predominant in tea, was associated with decreased glioma risk in a prospective cohort of men and women. Habitual consumption of foods and beverages containing flavan-3-ols and polymeric flavonoids may protect against the development of glioma. Funding Sources This work was supported by the U.S. National Institutes of Health.

Download Full-text

FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS

Journal of Prevention of Alzheimer's Disease ◽

10.14283/jpad.2016.122 ◽

2016 ◽

pp. 1-9

Author(s):

O. Rodriguez-Gomez ◽

A. Sanabria ◽

A. Perez-Cordon ◽

D. Sanchez-Ruiz ◽

C. Abdelnour ◽

...

Keyword(s):

Risk Factor ◽

Cognitive Impairment ◽

Cognitive Decline ◽

Diffusion Tensor ◽

Subjective Cognitive Decline ◽

Long Term Study ◽

Research Protocols ◽

Preclinical Ad ◽

Multimodal Biomarkers

Background: Long-term longitudinal studies with multimodal biomarkers are needed to delve into the knowledge of preclinical AD. Subjective cognitive decline has been proposed as a risk factor for the development of cognitive impairment. Thus, including individuals with SCD in observational studies may be a cost-effective strategy to increase the prevalence of preclinical AD in the sample. Objectives: To describe the rationale, research protocols and baseline characteristics of participants in the Fundació ACE Healthy Brain Initiative (FACEHBI). Design: FACEHBI is a clinical trial (EudraCT: 2014-000798-38) embedded within a long-term observational study of individuals with SCD. Setting: Participants have been recruited at the memory clinic of Fundació ACE (Barcelona) from two different sources: patients referred by a general practitioner and individuals from an Open House Initiative. Participants: 200 individuals diagnosed with SCD with a strictly normal performance in a comprehensive neuropsychological battery. Measurements: Individuals will undergo an extensive neuropsychological protocol, risk factor assessment and a set of multimodal biomarkers including florbetaben PET, structural and functional MRI, diffusion tensor imaging, determination of amyloid species in plasma and neurophthalmologic assessment with optical coherence tomography. Results: Two hundred individuals have been recruited in 15 months. Mean age was 65.9 years; mean MMSE was 29.2 with a mean of 14.8 years of education. Conclusions: FACEHBI is a long-term study of cognition, biomarkers and lifestyle that has been designed upon an innovative symptom-based approach using SCD as target population. It will shed light on the pathophysiology of preclinical AD and the role of SCD as a risk marker for the development of cognitive impairment.

Download Full-text